| Basics |
MannKind Corporation
MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
|
| IPO Date: |
July 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.69B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 3.02%
|
| Avg Daily Range (30 D): |
$0.13 | 2.36%
|
| Avg Daily Range (90 D): |
$0.10 | 2.32%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.79M |
| Avg Daily Volume (30 D): |
3.94M |
| Avg Daily Volume (90 D): |
3.6M |
| Trade Size |
| Avg Trade Size (Sh.): |
306 |
| Avg Trade Size (Sh.) (30 D): |
202 |
| Avg Trade Size (Sh.) (90 D): |
190 |
| Institutional Trades |
| Total Inst.Trades: |
3,727 |
| Avg Inst. Trade: |
$1.55M |
| Avg Inst. Trade (30 D): |
$1.69M |
| Avg Inst. Trade (90 D): |
$1.65M |
| Avg Inst. Trade Volume: |
.24M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.82M |
| Avg Closing Trade (30 D): |
$2.27M |
| Avg Closing Trade (90 D): |
$1.98M |
| Avg Closing Volume: |
360.11K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$.11
|
$
|
$.04
|
|
Diluted EPS
|
$.11
|
$
|
$.04
|
|
Revenue
|
$ 301.74M
|
$ 76.53M
|
$ 78.35M
|
|
Gross Profit
|
$ 285.36M
|
$ 71.92M
|
$ 74.59M
|
|
Net Income / Loss
|
$ 32.8M
|
$ .67M
|
$ 13.16M
|
|
Operating Income / Loss
|
$ 66.85M
|
$ 5.3M
|
$ 22.29M
|
|
Cost of Revenue
|
$ 16.38M
|
$ 4.61M
|
$ 3.77M
|
|
Net Cash Flow
|
$ -39.63M
|
$ 9.7M
|
$ .98M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
